Items | Drug development strategy | Trial planning | Trial conduct | Studied drug | P |
---|---|---|---|---|---|
Study design | |||||
 Parallel assignment (n = 171)b | 57 (33.3) | 58 (33.9) | 9 (5.3) | 47 (27.5) | 0.164d |
 Crossover assignment (n = 111)b | 31 (27.9) | 30 (27.0) | 15 (13.5) | 35 (31.5) | |
 Single group assignment (n = 32) | 10 (31.3) | 12 (37.5) | 1 (3.1) | 9 (28.1) | |
Blinding status | |||||
 Open label (n = 179)b | 49 (27.4) | 58 (32.4) | 18 (10.1) | 54 (30.2) | 0.240e |
 Single blind (n = 14)b | 5 (35.7) | 5 (35.7) | 2 (14.3) | 2 (14.3) | |
 Double blind (n = 121) | 44 (36.4) | 37 (30.6) | 5 (4.1) | 35 (28.9) | |
No. of centers | |||||
 Single center trial (n = 144)b | 45 (31.3) | 45 (31.3) | 5 (3.5)f | 49 (34.0) | 0.028d |
 Multiple center trial (n = 170) | 53 (31.2) | 55 (32.4) | 20 (11.8) | 42 (24.7) | |
Sample size c | |||||
  < 100 participants (n = 157)b | 48 (30.6) | 48 (30.6) | 18 (11.5) | 43 (27.4) | 0.002d |
 100–499 participants (n = 109)b | 37 (33.9) | 42 (38.5) | 7 (6.4) | 23 (21.1) | |
  > 500 participants (n = 37)b | 7 (18.9) | 7 (18.9) | 2 (5.4) | 21 (56.8)g | |
Has enrolled participants | |||||
 Yes (n = 136)b | 26 (19.1)h | 37 (27.2) | 10 (7.4) | 63 (46.3)h | < 0.001d |
 No (n = 178)b | 72 (40.4) | 63 (35.4) | 15 (8.4) | 28 (15.7) |